{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:51:00Z","timestamp":1778946660165,"version":"3.51.4"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Aim: In patients with hepatitis C virus-related liver cirrhosis (LC) who achieve sustained virological responses (SVRs) through treatment with direct-acting antiviral agents (DAAs), it remains unclear whether there are improvements in gastroesophageal varices (GEVs) and portal hypertension. We investigated changes in liver function and GEVs that occurred after DAA therapy. Materials and Methods: We evaluated the medical records of 195 patients with hepatitis C virus-related LC who received DAAs. A total of 171 patients achieved SVRs, among whom 36 had GEVs before or after receiving DAA therapy. The liver function, fibrosis, and GEVs were re-evaluated every 6 months after receiving DAA therapy. The risk factors for progressive GEVs were investigated. Results: DAA therapy resulted in improvements in liver function (indicated by aspartate transaminase, alanine transaminase, and serum albumin levels) and fibrosis (indicated by type IV collagen levels and the Fibrosis-4 index). After receiving DAA therapy, 27 patients had stable GEVs and 9 had progressive GEVs. With respect to GEV grades before DAA therapy, there was a significant difference between patients with stable and progressive GEVs (p = 0.027). Presence of grade-2 GEVs before starting DAA therapy was a risk factor for GEV progression (odds ratio: 5.83; p = 0.04). Patients with grade-2 GEVs had significantly shorter progression-free periods than those with grade &lt; 2 GEVs (p = 0.025). Conclusions: DAA therapy does not ameliorate GEVs. Furthermore, grade-2 GEVs can worsen after DAA therapy. Therefore, patients with GEVs of grades \u2265 2 should undergo endoscopic surveillance after receiving DAAs.<\/jats:p>","DOI":"10.3390\/medicina58081077","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:46:24Z","timestamp":1660124784000},"page":"1077","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis"],"prefix":"10.3390","volume":"58","author":[{"given":"Hiroshi","family":"Hisanaga","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Takedatsu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Emori","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhumi","family":"Kunitake","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Nakane","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-7564","authenticated-orcid":false,"given":"Shuhei","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Mitsuyama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Torimura","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume 830-0011, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S2468-1253(17)30053-5","article-title":"Shortening the duration of therapy for chronic hepatitis C infection","volume":"2","author":"Emmanuel","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"Webster","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1053\/j.gastro.2008.03.007","article-title":"Portal hypertension and its complications","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2013.10.018","article-title":"A MELD-based model to determine risk of mortality among patients with acute variceal bleeding","volume":"146","author":"Reverter","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MCG.0000000000000733","article-title":"Child-Turcotte-Pugh class is best at stratifying risk in variceal hemorrhage: Analysis of a US multicenter prospective study","volume":"51","author":"Fortune","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: A long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"46","author":"Sanyal","year":"2007","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"ref_10","first-page":"CD012143","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"9","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","author":"Afdhal","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.15586","article-title":"Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding","volume":"51","author":"Moon","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yuri, Y., Nishikawa, H., Enomoto, H., Yoh, K., Iwata, Y., Sakai, Y., Kishino, K., Ikeda, N., Takashima, T., and Aizawa, N. (2019). Impact of sustained virological response for gastroesophageal varices in hepatitis-C-virus-related liver cirrhosis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010095"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00535-019-01619-0","article-title":"Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients","volume":"55","author":"Torras","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_18","first-page":"42","article-title":"Endoscopic management of esophagogastric varices in Japan","volume":"2","author":"Miyaaki","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.21037\/atm.2020.01.122","article-title":"Multiparametric radiomics nomogram may be used for predicting the severity of esophageal varices in cirrhotic patients","volume":"8","author":"Wan","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/jgh.13788","article-title":"Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response","volume":"32","author":"Tada","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/jvh.13416","article-title":"Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"28","author":"Laursen","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3851\/IMP3186","article-title":"Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis","volume":"23","author":"Persico","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/apt.13823","article-title":"All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: Observations through HCV-TARGET database","volume":"45","author":"Reddy","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"Aghemo","year":"2012","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.3748\/wjg.v23.i26.4669","article-title":"Impact of hepatitis C oral therapy in portal hypertension","volume":"23","author":"Marinho","year":"2017","journal-title":"World J. Gastroenterol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1077\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:06:49Z","timestamp":1760141209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["medicina58081077"],"URL":"https:\/\/doi.org\/10.3390\/medicina58081077","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]}}}